Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology

D. Giugliano, L. De Nicola, M.I. Maiorino, G. Bellastella, C. Garofalo, P. Chiodini, A. Ceriello, K. Esposito

Research output: Contribution to journalArticlepeer-review

Abstract

Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. © 2020 The Author(s).
Original languageEnglish
JournalCardiovasc. Diabetol.
Volume19
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • Diabetic kidney disease
  • MACE
  • SGLT-2 inhibitors
  • Statin therapy
  • Type 2 diabetes
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • placebo
  • renin inhibitor
  • sodium glucose cotransporter 2 inhibitor
  • albuminuria
  • cardiovascular disease
  • cardiovascular response
  • cardiovascular risk
  • diabetic nephropathy
  • disease association
  • disease severity
  • drug efficacy
  • estimated glomerular filtration rate
  • high risk population
  • human
  • kidney function
  • meta analysis
  • non insulin dependent diabetes mellitus
  • outcome assessment
  • renal protection
  • Review
  • risk reduction
  • adverse event
  • chronic kidney failure
  • clinical trial (topic)
  • drug effect
  • kidney
  • pathophysiology
  • protection
  • risk assessment
  • risk factor
  • treatment outcome
  • Cardiovascular Diseases
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2
  • Diabetic Nephropathies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Kidney
  • Protective Factors
  • Renal Insufficiency, Chronic
  • Risk Assessment
  • Risk Factors
  • Sodium-Glucose Transporter 2 Inhibitors
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology'. Together they form a unique fingerprint.

Cite this